ID   HVEM 18.10
AC   CVCL_B7FA
DR   Wikidata; Q112929806
RX   Patent=US10005839;
RX   PubMed=23692853;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4752.
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; Q92956; Human TNFRSF14/CD270.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 23-06-22; Last updated: 21-03-23; Version: 3
//
RX   Patent=US10005839;
RA   Olive D., Pasero C., Gertner-Dardenne J.;
RT   "Antagonist of the BTLA/HVEM interaction for use in therapy.";
RL   Patent number US10005839, 26-Jun-2018.
//
RX   PubMed=23692853; DOI=10.1182/blood-2012-11-464685;
RA   Gertner-Dardenne J., Fauriat C., Orlanducci F., Thibult M.-L.,
RA   Pastor S., Fitzgibbon J., Bouabdallah R., Xerri L., Olive D.;
RT   "The co-receptor BTLA negatively regulates human Vgamma9Vdelta2 T-cell
RT   proliferation: a potential way of immune escape for lymphoma cells.";
RL   Blood 122:922-931(2013).
//